Clarkston Capital Partners LLC Grows Position in Align Technology, Inc. $ALGN

Clarkston Capital Partners LLC raised its position in Align Technology, Inc. (NASDAQ:ALGN) by 17.3% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 112,365 shares of the medical equipment provider’s stock after purchasing an additional 16,575 shares during the quarter. Clarkston Capital Partners LLC owned 0.16% of Align Technology worth $21,274,000 as of its most recent SEC filing.

Several other institutional investors have also added to or reduced their stakes in ALGN. Avantax Advisory Services Inc. raised its holdings in shares of Align Technology by 22.2% in the first quarter. Avantax Advisory Services Inc. now owns 3,221 shares of the medical equipment provider’s stock worth $512,000 after buying an additional 586 shares during the period. GSA Capital Partners LLP increased its stake in Align Technology by 121.9% in the first quarter. GSA Capital Partners LLP now owns 5,120 shares of the medical equipment provider’s stock worth $813,000 after purchasing an additional 2,813 shares during the period. Banque Cantonale Vaudoise bought a new stake in shares of Align Technology during the first quarter worth $364,000. XTX Topco Ltd bought a new stake in shares of Align Technology during the first quarter worth $1,821,000. Finally, Modera Wealth Management LLC boosted its stake in shares of Align Technology by 3.2% during the first quarter. Modera Wealth Management LLC now owns 15,347 shares of the medical equipment provider’s stock valued at $2,438,000 after purchasing an additional 481 shares during the period. Institutional investors own 88.43% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on ALGN shares. HSBC lifted their price objective on shares of Align Technology from $140.00 to $150.00 in a report on Friday, October 31st. Weiss Ratings lowered Align Technology from a “hold (c-)” rating to a “sell (d+)” rating in a report on Wednesday, October 8th. Wells Fargo & Company reduced their price objective on Align Technology from $199.00 to $181.00 and set an “overweight” rating on the stock in a report on Thursday, October 30th. Zacks Research raised Align Technology from a “strong sell” rating to a “hold” rating in a research report on Tuesday, September 30th. Finally, UBS Group dropped their price objective on shares of Align Technology from $160.00 to $155.00 and set a “neutral” rating on the stock in a research note on Thursday, October 16th. One equities research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, seven have assigned a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat.com, Align Technology has an average rating of “Hold” and a consensus price target of $175.45.

Align Technology Stock Down 0.2%

Shares of Align Technology stock opened at $147.23 on Friday. The company has a market cap of $10.56 billion, a P/E ratio of 28.53, a PEG ratio of 1.49 and a beta of 1.84. The firm’s 50 day moving average price is $134.14 and its 200-day moving average price is $156.95. Align Technology, Inc. has a 52-week low of $122.00 and a 52-week high of $246.19.

Align Technology (NASDAQ:ALGN) last announced its earnings results on Wednesday, October 29th. The medical equipment provider reported $2.61 earnings per share for the quarter, beating the consensus estimate of $2.38 by $0.23. Align Technology had a net margin of 9.50% and a return on equity of 14.06%. The company had revenue of $995.69 million during the quarter, compared to the consensus estimate of $980.75 million. During the same period last year, the firm earned $2.35 earnings per share. Align Technology’s revenue was up 1.8% compared to the same quarter last year. Align Technology has set its Q4 2025 guidance at EPS. As a group, equities research analysts forecast that Align Technology, Inc. will post 7.98 EPS for the current fiscal year.

Align Technology declared that its Board of Directors has authorized a stock buyback program on Tuesday, August 5th that allows the company to buyback $200.00 million in outstanding shares. This buyback authorization allows the medical equipment provider to purchase up to 2% of its stock through open market purchases. Stock buyback programs are generally an indication that the company’s board of directors believes its shares are undervalued.

Align Technology Company Profile

Align Technology, Inc designs, manufactures, and markets Invisalign clear aligners, and iTero intraoral scanners and services for orthodontists and general practitioner dentists in the United States, Switzerland, and internationally. The company's Clear Aligner segment offers comprehensive products, including Invisalign comprehensive package that addresses the orthodontic needs of younger patients, such as mandibular advancement, compliance indicators, and compensation for tooth eruption; and Invisalign First Phase I and Invisalign First Comprehensive Phase 2 package for younger patients generally between the ages of six and ten years, which is a mixture of primary/baby and permanent teeth.